Comparative Effectiveness of First-Line Tyrosine Kinase Inhibitors in ALK-Positive Metastatic Non-Small Cell Lung Cancer by Presence of Brain Metastases. (PubMed, Clin Lung Cancer) - Oct 7, 2026 - "There was no statistically significant difference in TTD, TTNT, OS for brigatinib versus alectinib and lorlatinib; however, the small brigatinib and lorlatinib samples limit statistical power. More patients on 1L alectinib or brigatinib achieved full prescribing dose and stayed on it for longer compared to those on 1L lorlatinib."
HEOR • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Ajibade Ashaye; Christopher Danes; Chul Kim; Hoa H Le; Kyle Roney; Kyung Min Lee; Sharmistha Ghosh; Traci LeMasters; Viktor Chirikov; Yuanbin Chen
|